Modified VR-CAP, Alternating with Rituximab and High-dose Cytarabine: An Effective Pre-Transplant Induction Regimen for Mantle Cell Lymphoma
Publication date: Available online 17 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): S.D. Smith, S. Gandhy, A.K. Gopal, P. Reddy, M. Shadman, B.G. Till, R.C. Lynch, S. Kanan, A. Cowan, L. Low, B.T. Hill (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 17, 2018 Category: Cancer & Oncology Source Type: research

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma
We report a relapsed and refractory Multiple Myeloma (RRMM) and AL Amyloidosis patient responding to elotuzumab/lenalidomide/dexamethasone (ERD). A 51-year-old woman presented with a right mandibular mass with positive Congo-red staining, clonal kappa free-light chains (κFLC) and plasma cell proliferation. Workup was consistent with κFLC amyloidosis and MM with nephrotic range proteinuria. After progression on several lines of therapy, she has near complete reversal of proteinuria while being maintained on ERD. This regimen should be tested in patients with AL Amyloidosis. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 16, 2018 Category: Cancer & Oncology Source Type: research

Histiocytic Sarcoma Associated with Follicular Lymphoma: Evidence for Dramatic Response with Rituximab and Bendamustine Alone and a Review of the Literature
Conclusionsand Relevance: The combination of rituximab and bendamustine warrants further investigation in the treatment of HS, especially those originating from prior follicular lymphoma. Modern immunohistochemical and molecular profiling techniques are beginning to reveal heterogeneity amongst HS tumors and potentially therapeutic targets. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 13, 2018 Category: Cancer & Oncology Source Type: research

Cytomegalovirus reactivation in an extensively pretreated multiple myeloma patient during daratumumab treatment
Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kristine A. Frerichs, Patricia W.C. Bosman, Inger S. Nijhof, S. Zweegman, Niels W.C.J. van de Donk (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 13, 2018 Category: Cancer & Oncology Source Type: research

EBV-positive Mucocutaneous Ulcer: A Case Report and Review of the First 100 Published Cases
Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ryan B. Sinit, Kathleen L. Horan, Russell K. Dorer, David M. AboulafiaAbstractIn 2016, the World Health Organization provisionally classified Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) as a lymphoid neoplasm under the subcategory of mature B-cell neoplasms. EBVMCU is manifested as a well-circumscribed ulcer, typically unifocal, and of the oropharynx, gastrointestinal tract, or skin. Immunohistochemical studies of these ulcers reveal monoclonal B-immunoblasts staining positively for CD20, CD30, EBER...
Source: Clinical Lymphoma Myeloma and Leukemia - October 13, 2018 Category: Cancer & Oncology Source Type: research

Bexarotene in Patients with Peripheral T-cell Lymphomas: Results of a Retrospective Study
ConclusionBexarotene monotherapy is well-tolerated and has encouraging activity in PTCL that warrants further investigation. This agent should be considered for further prospective trials in this setting. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 13, 2018 Category: Cancer & Oncology Source Type: research

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: a single center experience
Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): AnnaLynn M. Williams, Andrea Baran, Carla Casulo, Patrick Reagan, Jonathan W. Friedberg, Margaret Helber, Jeremiah Moore, Elizabeth Baloga, Clive S. Zent, Paul M. BarrAbstractBackgroundAs oral targeted agents, such as ibrutinib, become more widely used understanding the impact of suboptimal dosing on overall and progression-free survival outside of clinical trials is imperative.MethodsData on ibrutinib discontinuation, dose reductions and treatment interruptions were collected on 170 non-Hodgkin lymphoma (NHL) and chr...
Source: Clinical Lymphoma Myeloma and Leukemia - October 13, 2018 Category: Cancer & Oncology Source Type: research

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma
Publication date: Available online 5 September 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Caroline M. Hsu, John M. Bennett, Brea LipeAbstractHemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory state characterized by phagocytosis of hematopoietic elements. It may be triggered by infection, malignancy, and autoimmune disorders and often progresses to multiorgan failure and even death.A 59-year-old man presented to our hospital for recurrent fevers in the setting of known IgA multiple myeloma complicated by end-stage renal disease requiring dialysis. Infectious workup was negative, and he was dia...
Source: Clinical Lymphoma Myeloma and Leukemia - October 9, 2018 Category: Cancer & Oncology Source Type: research

Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms
ConclusionOn the basis of our results, a new scoring system for thrombosis risk in PV could be made, while PMF prognostic model may be expanded for better recognition of potential thrombotic risk factors. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 7, 2018 Category: Cancer & Oncology Source Type: research

Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries
ConclusionOur data indicates that bortezomib and transplant are still an unmet medical necessity in public systems. In the complex puzzle of myeloma drug access in LATAMC, important issues, such as the adjustment of disparities between health systems, the incorporation of new drugs with an economic cost-effectiveness view, and the re-establishment of essential old drugs, can be a platform to the future. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 7, 2018 Category: Cancer & Oncology Source Type: research

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis
Publication date: Available online 29 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Moussab Damlaj, Mohsen Al-Zahrani, Ghulam Syed, Giamal Gmati, Bader Alahmari, Tabrez Pasha, Ayman Alhejazi, Ahmed AlaskarAbstractBackgroundResponse-adapted therapy in advanced classical Hodgkin lymphoma (cHL) using interim functional imaging (IFI) is under active investigation.Patients and MethodsWe retrospectively examined patients with advanced cHL receiving 2 front-line regimens stratified by IFI results at our institution. Time to endpoint analysis was estimated using the method of Kaplan-Meier with log ranks. Cox ...
Source: Clinical Lymphoma Myeloma and Leukemia - October 4, 2018 Category: Cancer & Oncology Source Type: research

Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma
ConclusionsForty percent of patients receiving DA-EPOCH-R therapy developed LACs, almost one-half of whom experienced grade 3 toxicities. The complication rate was significantly greater in patients undergoing therapy with DA-EPOCH-R compared with those undergoing R-CHOP therapy. Clinicians need to balance these risks when selecting therapy. Future studies are needed to evaluate prophylactic anticoagulation strategies in this population. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - October 4, 2018 Category: Cancer & Oncology Source Type: research

Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma
Publication date: Available online 20 September 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joshua Richter, Sundar JagannathAbstractDuring the past decade, the survival outcomes of patients with multiple myeloma (MM) have dramatically improved, not only owing to the advent of a number of novel therapies, but also to the deepening insight regarding how to best use these options. Triplet-based induction regimens can yield overall response rates of ≤ 100%. In the relapsed and refractory setting, we have a multitude of doublet and triplet options available with high and durable response rates. The addi...
Source: Clinical Lymphoma Myeloma and Leukemia - October 4, 2018 Category: Cancer & Oncology Source Type: research

Editorial Board
Publication date: October 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 10Author(s): (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 22, 2018 Category: Cancer & Oncology Source Type: research

Table of Contents
Publication date: October 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 10Author(s): (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 22, 2018 Category: Cancer & Oncology Source Type: research

Corrigendum
Publication date: October 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 10Author(s): (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 22, 2018 Category: Cancer & Oncology Source Type: research

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States
ConclusionREVEAL enrollment data inform our understanding of the baseline demographics, diagnostic approach, disease characteristics, and treatment patterns of patients with PV in the United States. Longitudinal real-world data collected in this study will complement information collected during randomized controlled clinical trials. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2018 Category: Cancer & Oncology Source Type: research

Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients
ConclusionOur proposed nomogram based on Eastern Cooperative Oncology Group performance status, Ann Arbor stage, albumin-to-globulin ratio, and platelet count provides an individualized risk estimate of OS in patients with ENKTL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2018 Category: Cancer & Oncology Source Type: research

Society of Hematologic Oncology (SOHO) State of the Art Update & Next Questions: Multiple Myeloma
Publication date: Available online 20 September 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joshua Richter, Sundar JagannathAbstractOver the last decade the survival outcomes in Multiple Myeloma (MM) have dramatically improved thanks to not only the advent of a number of novel therapies; but also, to the deepening insight regarding how to best utilize these options. Triplet-based induction regimens can yield overall response rates of up to 100%. In the relapsed and refractory setting, we have a multitude of doublet and triplet options with high and durable response rates. The addition of monoclonal antibod...
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2018 Category: Cancer & Oncology Source Type: research

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM
ConclusionvWF levels measured in the serum could become an important prognostic marker in patients with WM and requires further investigation. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 15, 2018 Category: Cancer & Oncology Source Type: research

Added Value of Contrast-Enhanced T1-Weighted and Diffusion-Weighted Sequences for Characterization of Incidental Findings on Whole Body Magnetic Resonance Imaging in Plasma-Cell Disorders
ConclusionIncidental findings are common, but the majority are of no clinical consequence. No additional cancers were noted in our series. DWI and CE T1-W sequences increased diagnostic confidence in 50% of indeterminate findings and may reduce the need for further investigation. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 13, 2018 Category: Cancer & Oncology Source Type: research

Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity
ConclusionWe did not observe cardiotoxicity from bortezomib-based chemotherapy despite very intensive evaluation with multiple modalities. Neither cumulative nor transient alterations were found in our metrics, suggesting that bortezomib is safe from a cardiovascular standpoint for patients free of cardiovascular disease. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2018 Category: Cancer & Oncology Source Type: research

Identifying prognostic factors that influence outcome of childhood acute myeloid leukemia in first relapse in Saudi Arabia: Results of the multicenter SAPHOS study
ConclusionsrAML remains a clinical challenge. Genetic variability in outcomes was observed. A majority of patients with inv(16) were successfully salvaged post relapse while patients with 11q23 rearrangement had a poor prognosis. Only a third of those with t(8;21) rAML survived. Better access to SCT in HIDC is needed. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2018 Category: Cancer & Oncology Source Type: research

Outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for Hodgkin lymphomas: a retrospective multicentre experience by the Rete Ematologica Pugliese (REP)
ConclusionsAllogeneic SCT results extend survival in selected patients with relapsed/refractory HL, showing low treatment-related mortality. Patients with active disease at the time of allogeneic transplantation have poor outcomes. Allogeneic SCT may be an effective salvage strategy for patients who relapse after an autologous SCT. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 12, 2018 Category: Cancer & Oncology Source Type: research

Improved Survival of Elderly-fit Patients With Acute Myeloid Leukemia Requiring Intensive Therapy: 3-Year Multicenter Analysis From TALWG
ConclusionOur study confirms the high prevalence of AML in elderly patients with generally poor outcomes. Selected patients with a good performance status and those who received intensive induction treatment could have a long-term survival. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 11, 2018 Category: Cancer & Oncology Source Type: research

Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma involving the Mesentery with Volumetric Image Guided Intensity Modulated Radiation Therapy
ConclusionMesenteric involvement of DLBCL can be successfully targeted with localized ISRT fields using IMRT and daily CT-image guidance. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 11, 2018 Category: Cancer & Oncology Source Type: research

The influence of blood count, cardiovascular risks, inherited thrombophilia and JAK2 V617F burden allele on the type of thrombosis in patients with Ph(-) myeloproliferative neoplasms
ConclusionBased on our results, a new scoring system for thrombosis risk in PV could be made while PMF prognostic model may be expanded for better recognition of potential thrombotic risk factors. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 11, 2018 Category: Cancer & Oncology Source Type: research

Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France
ConclusionThese results suggest that effective treatment options in MM can help maintain HRQoL by influencing treatment response levels and delaying disease progression. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 6, 2018 Category: Cancer & Oncology Source Type: research

Case Report: Hemophagocytic lymphohistiocytosis in a multiple myeloma patient
Publication date: Available online 5 September 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Caroline M. Hsu, John M. Bennett, Brea LipeAbstractHemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory state characterized by phagocytosis of hematopoietic elements. It may be triggered by infection, malignancy, and autoimmune disorders and often progresses to multiorgan failure and even death.A 59-year-old man presented to our hospital for recurrent fevers in the setting of known IgA multiple myeloma complicated by end-stage renal disease requiring dialysis. Infectious workup was negative, and he was dia...
Source: Clinical Lymphoma Myeloma and Leukemia - September 6, 2018 Category: Cancer & Oncology Source Type: research

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-Agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56 Positive Multiple Myeloma
We present the results of a completed phase I trial of single-agent lorvotuzumab mertansine, a unique antibody-drug conjugate targeting CD56, which is frequently expressed in MM. Thirty-seven patients with relapsed MM were enrolled in a dose-escalation phase I clinical trial to determine the maximum tolerated dose (MTD) of lorvotuzumab mertansine (112 mg/m2), followed by an expansion phase at the MTD. Despite a high proportion of patients with RRMM (56.8%), stable disease or better was noted in 42.9% patients and these patients had a long duration of response (median 15.5 months). The adverse event (AE) profile was favorab...
Source: Clinical Lymphoma Myeloma and Leukemia - September 6, 2018 Category: Cancer & Oncology Source Type: research

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment Resistant Immunoglobulin Light Chain Amyloidosis with Multiple Myeloma
We report a relapsed and refractory Multiple Myeloma (RRMM) and AL Amyloidosis patient responding to elotuzumab/lenalidomide/dexamethasone (ERD). A 51-year-old woman presented with a right mandibular mass with positive Congo-red staining, clonal kappa free-light chains (κFLC) and plasma cell proliferation. Workup was consistent with κFLC amyloidosis and MM with nephrotic range proteinuria. After progression on several lines of therapy, she has near complete reversal of proteinuria while being maintained on ERD. This regimen should be tested in patients with AL Amyloidosis. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 6, 2018 Category: Cancer & Oncology Source Type: research

Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
Publication date: Available online 5 September 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Xavier Leleu, Thomas G. Martin, Hermann Einsele, Roger M. Lyons, Brian GM. Durie, Karim S. Iskander, Sikander AilawadhiABSTRACTProteasome inhibition is an established treatment strategy for patients with multiple myeloma as proteasome inhibitors selectively target and disrupt the protein metabolism of aberrant plasma cells. Since the introduction of the first-in-class proteasome inhibitor bortezomib, the therapeutic landscape for multiple myeloma has shifted with the development of next-generation proteasome inhibito...
Source: Clinical Lymphoma Myeloma and Leukemia - September 6, 2018 Category: Cancer & Oncology Source Type: research

Management of Polycythemia Vera: A survey of Canadian Physician Practice Patterns
Publication date: Available online 31 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Laura Anne Habib, Kevin H.M. Kuo, Tony Panzarella, Vikas Gupta, Martina TrinkausAbstract:BackgroundThe 2016 World Health Organization (WHO) revised classification criteria for the diagnosis of polycythemia vera (PV) allows for an earlier detection of masked PV. The literature is scarce about the clinical uptake of new diagnostic algorithms for PV. In a cohort of Canadian hematologists, we aimed to identify how the revised 2016 World Health Organization (WHO) diagnostic criteria of Polycythemia Vera (PV) are being incor...
Source: Clinical Lymphoma Myeloma and Leukemia - September 1, 2018 Category: Cancer & Oncology Source Type: research

A prognostic nomogram for overall survival in extranodal natural killer/T-cell lymphoma patients
ConclusionThe proposed nomogram based on ECOG PS, Ann Arbor stage, AGR and PC provides an individualized risk estimate of OS in patients with ENKTL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 29, 2018 Category: Cancer & Oncology Source Type: research

Complications Associated with Dose-Adjusted EPOCH-Rituximab Therapy for Non-Hodgkin Lymphoma.
ConclusionsForty percent of patients receiving DA-EPOCH-R therapy developed LAC, almost half of whom experienced grade 3 toxicities. The complication rate was significantly greater in patients undergoing therapy with DA-EPOCH-R, compared to R-CHOP. Clinicians need to balance these risks when selecting therapy. Future studies are needed to evaluate prophylactic anticoagulation strategies in this population. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 29, 2018 Category: Cancer & Oncology Source Type: research

Analysis of Availability and Access of anti- Myeloma drugs and Impact on the Management of Multiple Myeloma in Latin American Countries
Publication date: Available online 29 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Roberto Jose Pessoa de Magalhaes Filho, Edvan Crusoe, Eloisa Riva, Willen Bujan, Guilhermo Conte, Juan Ramon Navarro Cabrera, Diana Katerine Garcia, Guilhermo Quintero Vega, Jose Macias, Jose Willian Oliveros Alvear, Mercedes Royg, Lidiane Andino Neves, Jose Luis Lopez Dopico, German Espino, Douglas Rosales Ortiz, Zurelis Socarra, Dorotea Fantl, Guillermo J. Ruiz-Arguelles, Angelo Maiolino, Vania Tietsche De Moraes Hungria (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 29, 2018 Category: Cancer & Oncology Source Type: research

The adverse consequences of initial watchful waiting for patients with follicular lymphoma
Publication date: Available online 29 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): G.A. Davies, S. Ghosh, D.H. Oh, M. Manna, A.C. Peters, C.A. Stewart, D.A. StewartAbstractBackgroundPatients with low tumor burden follicular lymphoma (FL) are commonly managed with watchful waiting (WW). The incidence of organ dysfunction and/or transformation at disease progression, and subsequent impact on outcomes is poorly understood.Patients and MethodsPatients managed with WW during 1994-2011 were identified through the Alberta Lymphoma Database. Individuals receiving immediate R-chemotherapy were identified as a...
Source: Clinical Lymphoma Myeloma and Leukemia - August 29, 2018 Category: Cancer & Oncology Source Type: research

Clinical and Disease Characteristics From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
This report summarizes the demographics and clinical characteristics of patients at enrollment (baseline).Patients (N=2510) were median age 67.0 years, 54.2% male, and 89.1% white. The median time from PV diagnosis to study enrollment was 4.0 (range, 0–56.3) years. Most patients (89.7%) were diagnosed following an abnormal blood test. Less than half (49.3%) underwent JAK2 mutation analysis, of whom 95.8% were JAK2V617F mutation-positive; less than 1% were positive for JAK2 exon 12 mutations. At enrollment, 47.7% of patients had elevated hematocrit (>45%), 35.8% had elevated platelets (>400 × 109/L), and 3...
Source: Clinical Lymphoma Myeloma and Leukemia - August 29, 2018 Category: Cancer & Oncology Source Type: research

Impact of consolidation cycles before allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission
This study evaluated the impact of HDAC consolidation cycles before allo-HCT on 194 patients with AML in first complete remission between 1998 and 2014. The patients were reclassified into three groups: no consolidation (C0, n=20), 1 consolidation (C1, n=115), and ≥2 consolidations (C2, n=59) by the pre-HCT consolidation cycles. The 3-year relapse-free survival (RFS) was 45.9%, 66.9%, and 73.3% for the C0, C1, and C2 groups, respectively (P=0.064), while the 3-year overall survival rate was 35.0%, 55.2%, and 67.5%, respectively (P=0.106). The cumulative incidence of acute graft-versus-host disease (GVHD) was higher in t...
Source: Clinical Lymphoma Myeloma and Leukemia - August 29, 2018 Category: Cancer & Oncology Source Type: research

Interim Functional Imaging Is an Independent Predictor of Progression Free Survival in Advanced Classical Hodgkin Lymphoma – A Real World Analysis
Publication date: Available online 29 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Moussab Damlaj, Mohsen Al-Zahrani, Ghulam Syed, Giamal Gmati, Bader Alahmari, Tabrez Pasha, Ayman Alhejazi, Ahmed AlaskarAbstractBackgroundResponse adapted therapy in advanced classical Hodgkin lymphoma (cHL) using interim functional imaging (IFI) is under active investigation.MethodsWe retrospectively examined patients with advanced cHL receiving two front line regimens stratified by IFI results at our institution. Time to endpoint analysis was estimated using the method of Kaplan and Meir with log ranks. Cox regressi...
Source: Clinical Lymphoma Myeloma and Leukemia - August 29, 2018 Category: Cancer & Oncology Source Type: research

Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Publication date: Available online 27 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jean El-Cheikh, Nour M. Moukalled, Haidar El Darsa, Radwan Massoud, Souha S. Kanj, Rami Mahfouz, Ali Bazarbachi (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 28, 2018 Category: Cancer & Oncology Source Type: research

TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma
In this study we examined the combined effect of both of these risk factors.Patients and MethodsPatients diagnosed with MCL between January 2000 and December 2014 (n = 74) were evaluated. Forty-eight of them had available material for TP53 and cytogenetic examination. We analyzed the prognostic effect of combined TP53mut and CK in the cohort of patients treated with rituximab-containing therapy.ResultsThree-year (3-y) overall survival (OS) and 3-y progression-free survival (PFS) in CK patients were shorter compared with non-CK (P = .001 for OS; P = .02 for PFS). TP53mut was a predictor of shorter survival co...
Source: Clinical Lymphoma Myeloma and Leukemia - August 24, 2018 Category: Cancer & Oncology Source Type: research

Efficacy and toxicity of idarubicin versus high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: A systematic review and meta-analysis
ConclusionsThe rate of complete response after the first course of induction therapy was significantly higher among adult patients with AML who received IDA as a part of induction therapy compared with those who received HDD. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 23, 2018 Category: Cancer & Oncology Source Type: research

Elevated Von Willebrand Factor Antigen Serum Levels Are Associated with Poor Prognosis and Circulating Adamts-13 Antigen levels Are Reduced and Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of von Willebrand Factor in Patients with Symptomatic Waldenstrom’s Macroglobulinemia
In conclusion, vWF measured in the serum, may become an important prognostic marker in WM and needs further investigation. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 23, 2018 Category: Cancer & Oncology Source Type: research

Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATETM study of ibrutinib vs ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma
Publication date: Available online 18 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jacqueline C. Barrientos, Susan O'Brien, Jennifer R. Brown, Neil E. Kay, Nishitha M. Reddy, Steven Coutre, Constantine Tam, Stephen Mulligan, Ulrich Jaeger, Stephen Devereux, Christopher Pocock, Tadeusz Robak, Stephen J. Schuster, Anna Schuh, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Gavin Cull, Mike HamblinAbstractBackgroundIbrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic l...
Source: Clinical Lymphoma Myeloma and Leukemia - August 18, 2018 Category: Cancer & Oncology Source Type: research

Editorial Board
Publication date: September 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 9Author(s): (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 15, 2018 Category: Cancer & Oncology Source Type: research

Table of Contents
Publication date: September 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 9Author(s): (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 15, 2018 Category: Cancer & Oncology Source Type: research

Bortezomib-Based Chemotherapy in Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity
ConclusionWe did not observe cardiotoxicity from bortezomib-based chemotherapy despite very intensive evaluation with multiple modalities. There was neither cumulative nor transient alterations in our metrics, suggesting that bortezomib is safe from a cardiovascular standpoint in patients free of cardiovascular disease. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 14, 2018 Category: Cancer & Oncology Source Type: research

Genetic Mutations in B-Acute Lymphoblastic Leukemia Among African American and European American Children
ConclusionsOur study revealed aberrant genetic aberrations in signaling networks that may contribute to race-specific aspects of leukemogenesis. Our results suggest the value of WES as a tool for development of individual gene signatures and gene scores for AA and EA children afflicted by B-ALL. These findings may ultimately impact disease management and contribute to the elimination of disparate outcomes in AA children with B-ALL.Graphical abstract (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 14, 2018 Category: Cancer & Oncology Source Type: research

Added value of contrast-enhanced T1-weighted and diffusion-weighted sequences for characterisation of incidental findings on whole body magnetic resonance imaging (WBMRI) in plasma cell disorders
ConclusionIncidental findings are common but the majority are of no clinical consequence. No additional cancers were noted in our series. DWI and CE T1-W sequences increased diagnostic confidence in 50% of indeterminate findings; and may reduce the need for further investigation. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 14, 2018 Category: Cancer & Oncology Source Type: research